Literature DB >> 3258141

Natural variants of human immunodeficiency virus from patients with neurological disorders do not kill T4+ cells.

R Anand1.   

Abstract

Human immunodeficiency virus (HIV) has selective T4-cell tropism and is cytocidal to cells with the helper-inducer phenotype. Central nervous system dysfunctions can complicate full-blown acquired immunodeficiency syndrome (AIDS) but can also be present either in isolation or in the context of AIDS-related complex. Remarkably bland histopathological findings have been reported in some patients with AIDS dementia in the presence of severe clinical dysfunction. Thus, to understand the cytopathic properties of HIV, we recovered five viral isolates from 4 patients with neurological symptoms of AIDS and identified them as HIVs. The replication and cytocidal properties of these isolates were compared with lymphadenopathy-associated virus in vitro. All five isolates exhibited replication efficiency equivalent to lymphadenopathy-associated virus, but four isolates did not kill CD4 (T4+) cells. These findings provide evidence for the existence of replication-competent noncytocidal natural variants of HIV and raise the possibility that, in some AIDS patients, neurological disorders might be caused by HIV variants that are noncytocidal to T4 cells.

Entities:  

Mesh:

Year:  1988        PMID: 3258141     DOI: 10.1002/ana.410230718

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  2 in total

1.  Examination of brains of AIDS cases for human immunodeficiency virus and human cytomegalovirus nucleic acids.

Authors:  D G Walker; S Itagaki; K Berry; P L McGeer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

2.  Chronic cryptococcal meningitis in an intravenous drug addict without evidence of infection by HIV-1,2 in southern Italy.

Authors:  L Monno; G Angarano; M T Montagna; S Coppola; S Carbonara; A Bellisario
Journal:  Eur J Epidemiol       Date:  1994-12       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.